Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Active Proliferative Lupus Nephritis
NCT05138133Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of anifrolumab in lupus nephritis (LN), sponsored by AstraZeneca. Started Feb 2022; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05138133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138133.